Hetrombopag + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Thrombocytopenia
Conditions
Chemotherapy-Induced Thrombocytopenia
Trial Timeline
Nov 6, 2019 → Feb 22, 2023
NCT ID
NCT03976882About Hetrombopag + Placebo
Hetrombopag + Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Chemotherapy-Induced Thrombocytopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT03976882. Target conditions include Chemotherapy-Induced Thrombocytopenia.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-Induced Thrombocytopenia were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04737850 | Phase 3 | Completed |
| NCT03976882 | Phase 3 | Completed |
Competing Products
20 competing products in Chemotherapy-Induced Thrombocytopenia